Dogwood Therapeutics, Inc. (DWTX) stock
Close on Nov 12, 2026Market cap $38.07MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $38.07M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.59
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$25.18M
- EPS, diluted
- -$7.13
- Book value per share
- $1.88
- Diluted shares
- 34M
Trading
- Next earnings
- Mar 17, 2027 (estimated, before the open)
- Previous close
- $1.18
- Open
- $1.17
- Day's range
- $1.08 – $1.21
- Volume
- 119,888
- Average volume (20 days)
- 107,098
- Beta (5 years)
- 1.86
- 52-week range
- $0.90 – $7.04
- RSI (14 days)
- 41.5
- Volatility (1 year)
- 89.9%
- Relative volume
- 1.63×
- WACC
- 14.3%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | DWTX | S&P 500 | Difference | DWTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -18.2% | -2.7% | −15.6 pts | ||
| 3 months | -41.8% | -1.7% | −40.1 pts | ||
| Year to date | -73.1% | +11.9% | −85.0 pts | ||
| 1 year | -80.8% | +12.0% | −92.8 pts | ||
| 3 years | -94.2% | +78.2% | −172.4 pts | -61.3% | +21.2% |
| 5 years | -99.2% | +73.2% | −172.4 pts | -61.8% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Dogwood Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- Results
- Update
- Results
About Dogwood Therapeutics
Pharmaceutical Preparations
This clinical-stage biopharmaceutical company discovers and develops novel therapeutic candidates aimed at treating neuropathy and chronic pain disorders. Its development pipeline features Halneuron, a late-stage non-opioid analgesic derived from tetrodotoxin that selectively inhibits Nav 1.7 sodium channels to alleviate chemotherapy-induced neuropathic pain. Additional programs include SP16, a synthetic anti-inflammatory peptide designed to promote nerve regeneration and reduce nerve damage, alongside preclinical and clinical-stage antiviral therapies, IMC-1 and IMC-2, targeting functional somatic syndromes such as fibromyalgia and Long-COVID. Upon achieving regulatory approval, the company intends to commercialize its pipeline through pharmaceutical distribution partnerships targeting primary care physicians, oncologists, and anesthesiologists.
Company profile, executives and historyDogwood Therapeutics stock: common questions
What is Dogwood Therapeutics's stock price?
DWTX closed at $1.12 on Nov 12, 2026, down 5.08% on the day. Over the past 52 weeks it traded between $0.90 and $7.04.
What is Dogwood Therapeutics's market cap?
Dogwood Therapeutics was worth $38.07M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is DWTX's P/E ratio?
Dogwood Therapeutics lost money over fiscal 2025 (diluted EPS -$7.13), so it has no meaningful P/E ratio.
Does Dogwood Therapeutics pay a dividend?
No. Dogwood Therapeutics has not paid a cash dividend over the last twelve months.
When does Dogwood Therapeutics report earnings next?
Dogwood Therapeutics is expected to report Q4 FY2026 results on Mar 17, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has DWTX stock performed over the past year?
Including dividends, DWTX returned -80.8% over the past year, against +12.0% for the S&P 500.
Who are Dogwood Therapeutics's competitors?
Companies most similar to Dogwood Therapeutics by business, industry and size include SMNR, CTNM, IXHL, KTTA, XENE.
See a number that looks wrong?